Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eye diseases
Pharma
Outlook stock plummets as FDA again snubs wet AMD drug
For the second time, the FDA has declined to approve Outlook's anti-VEGF drug for the treatment of wet age-related macular degeneration.
Angus Liu
Aug 28, 2025 10:55am
Manufacturing issues cause FDA to delay decisions on Eylea HD
Aug 20, 2025 2:32pm
Lenz's Vizz wins FDA approval to crack large presbyopia market
Aug 1, 2025 10:45am
GLP-1 use in diabetes linked to possible eye disease risk: study
Jun 6, 2025 7:25am
Novartis expands collaboration with Shanghai Pharma in China
May 27, 2025 10:08am
Apellis' Syfovre faces tough road ahead in GA market: analyst
May 14, 2025 11:10am
